Spondyloarthritis & psoriatic arthritis
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies
Authors' conclusion
In patients with PsA receiving tofacitinib, five distinct trajectory groups were identified with different baseline characteristics and treatment outcomes, but no clear trends in AEs.
Study context
- Population
- Patients with psoriatic arthritis (PsA) receiving tofacitinib in two phase 3 studies (OPAL Broaden, OPAL Beyond)
- Participants
- 225 vs 226
- Comparison
- Tofacitinib 5 mg vs Tofacitinib 10 mg
- Tofacitinib 5 mgn = 225
- Tofacitinib 10 mgn = 226
- Outcome
- Distinct disease activity trajectory groups by PASDAS (VLDA/LDA/MoDA/HDA)
- Follow-up
- Month 6
Methodological detailsOPAL Broaden, OPAL Beyond, group-based trajectory modelling
- OPAL Broaden, OPAL Beyond
- Group-based trajectory modelling
Pooled result
As reported in the abstract
PASDAS trajectory groups
- Five trajectory groups identified for both tofacitinib doses
- 5
Safety
Adverse events (AEs) across trajectory groups
- No clear trends in AEs across groups
Original publication
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. RMD Open. Published 3 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →